HIV molecular immunology database

 

Search the Epitope Variant and Escape Mutation Database

Help


Found 5 matching records:

Displaying record number 55002

HXB2 Location  Gag(147-155)   Gag Epitope Map
View variants at this location
Epitope ISPRTLNAW   Epitope Alignment
Variants
raPRTLNAW   non-susceptible form
mSPRTLNAW   non-susceptible form; susceptible form
vSPRTLNAW   non-susceptible form; susceptible form
ltPRTLNAW   non-susceptible form; susceptible form
vtPRTLNAW   non-susceptible form; susceptible form
ISaRTLNAW   non-susceptible form; susceptible form
IaPRTLNAr   non-susceptible form
lSPRTLNAW   diminished response; susceptible form
Epitope Name ISP
Species (MHC/HLA human(B*57:01)

Variant Details

Showing all: 8 variant(s).


Variant ID.  1789
Epitope Seq.  ISPRTLNAW
Variant Seq.  raPRTLNAW
Mutations I/R S/A
Epitope Location I1R S2A
HXB2 Location I147R S148A
Mutation Type NSF: non-susceptible form
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note None of the patients tested recognized the variant.


Variant ID.  1790
Epitope Seq.  ISPRTLNAW
Variant Seq.  mSPRTLNAW
Mutations I/M
Epitope Location I1M
HXB2 Location I147M
Mutation Type NSF: non-susceptible form
SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note Some patients recognized the variant, some did not.


Variant ID.  1791
Epitope Seq.  ISPRTLNAW
Variant Seq.  vSPRTLNAW
Mutations I/V
Epitope Location I1V
HXB2 Location I147V
Mutation Type NSF: non-susceptible form
SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note Some patients recognized the variant, some did not.


Variant ID.  1792
Epitope Seq.  ISPRTLNAW
Variant Seq.  ltPRTLNAW
Mutations I/L S/T
Epitope Location I1L S2T
HXB2 Location I147L S148T
Mutation Type NSF: non-susceptible form
SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note Some patients recognized the variant, some did not.


Variant ID.  1793
Epitope Seq.  ISPRTLNAW
Variant Seq.  vtPRTLNAW
Mutations I/V S/T
Epitope Location I1V S2T
HXB2 Location I147V S148T
Mutation Type NSF: non-susceptible form
SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note Some patients recognized the variant, some did not.


Variant ID.  1794
Epitope Seq.  ISPRTLNAW
Variant Seq.  ISaRTLNAW
Mutations P/A
Epitope Location P3A
HXB2 Location P149A
Mutation Type NSF: non-susceptible form
SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note Some patients recognized the variant, some did not.


Variant ID.  1795
Epitope Seq.  ISPRTLNAW
Variant Seq.  IaPRTLNAr
Mutations S/A W/R
Epitope Location S2A W9R
HXB2 Location S148A W155R
Mutation Type NSF: non-susceptible form
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note None of the patients tested recognized the variant.


Variant ID.  1796
Epitope Seq.  ISPRTLNAW
Variant Seq.  lSPRTLNAW
Mutations I/L
Epitope Location I1L
HXB2 Location I147L
Mutation Type DR: diminished response
SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note Some patients recognized the variant at the level of the index peptide, some had diminished response.

References

Turnbull2006 Emma L. Turnbull, A. Ross Lopes, Nicola A. Jones, David Cornforth, Phillipa Newton, Diana Aldam, Pierre Pellegrino, Jo Turner, Ian Williams, Craig M. Wilson, Paul A. Goepfert, Mala K. Maini, and Persephone Borrow. HIV-1 Epitope-Specific CD8+ T Cell Responses Strongly Associated with Delayed Disease Progression Cross-Recognize Epitope Variants Efficiently. J. Immunol., 176(10):6130-6146, 15 May 2006. PubMed ID: 16670322. Show all entries for this paper.


Displaying record number 55001

HXB2 Location  Gag(162-172)   Gag Epitope Map
View variants at this location
Epitope KAFSPEVIPMF   Epitope Alignment
Variants
rAFSPEVIPMF   susceptible form
KnFSPEVIPMF   non-susceptible form; susceptible form
KgFSPEVIPMF   susceptible form
KAFSPEiIPMF   susceptible form
KAFnPEVIPMF   non-susceptible form; susceptible form
KgFnPEVIPMF   non-susceptible form; susceptible form
KAFnPEiIPMF   non-susceptible form; susceptible form
KAFSPgVIPMF   non-susceptible form
Epitope Name KAF
Species (MHC/HLA human(B*57:01)

Variant Details

Showing all: 8 variant(s).


Variant ID.  1797
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  rAFSPEVIPMF
Mutations K/R
Epitope Location K1R
HXB2 Location K162R
Mutation Type SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note This natural variant was recognized in all patients tested.


Variant ID.  1798
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KnFSPEVIPMF
Mutations A/N
Epitope Location A2N
HXB2 Location A163N
Mutation Type NSF: non-susceptible form
SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note About half of patients tested recognized the variant, other patients had reduced or no response.


Variant ID.  1799
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KgFSPEVIPMF
Mutations A/G
Epitope Location A2G
HXB2 Location A163G
Mutation Type SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note All patients recognized the variant at >60% of the response to the index peptide.


Variant ID.  1800
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KAFSPEiIPMF
Mutations V/I
Epitope Location V7I
HXB2 Location V168I
Mutation Type SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note All patients recognized the variant at >60% of the response to the index peptide.


Variant ID.  1801
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KAFnPEVIPMF
Mutations S/N
Epitope Location S4N
HXB2 Location S165N
Mutation Type NSF: non-susceptible form
SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note About half of patients tested recognized the variant, other patients had reduced or no response.


Variant ID.  1802
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KgFnPEVIPMF
Mutations A/G S/N
Epitope Location A2G S4N
HXB2 Location A163G S165N
Mutation Type NSF: non-susceptible form
SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note 2 patients had response about 80% of the response to the index peptide. Most patients had reduced or no response.


Variant ID.  1803
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KAFnPEiIPMF
Mutations S/N V/I
Epitope Location S4N V7I
HXB2 Location S165N V168I
Mutation Type NSF: non-susceptible form
SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note 1 patient had response comparable to the response to the index peptide. Most patients had reduced or no response.


Variant ID.  1804
Epitope Seq.  KAFSPEVIPMF
Variant Seq.  KAFSPgVIPMF
Mutations E/G
Epitope Location E6G
HXB2 Location E167G
Mutation Type NSF: non-susceptible form
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note None of the patients tested responded to this variant.

References

Turnbull2006 Emma L. Turnbull, A. Ross Lopes, Nicola A. Jones, David Cornforth, Phillipa Newton, Diana Aldam, Pierre Pellegrino, Jo Turner, Ian Williams, Craig M. Wilson, Paul A. Goepfert, Mala K. Maini, and Persephone Borrow. HIV-1 Epitope-Specific CD8+ T Cell Responses Strongly Associated with Delayed Disease Progression Cross-Recognize Epitope Variants Efficiently. J. Immunol., 176(10):6130-6146, 15 May 2006. PubMed ID: 16670322. Show all entries for this paper.


Displaying record number 55007

HXB2 Location  Gag(259-267)   Gag Epitope Map
View variants at this location
Epitope GEIYKRWII   Epitope Alignment
Variants
GdIYrRWII   non-susceptible form
rkIYKRWII   non-susceptible form
GdIYrkWIv   non-susceptible form
GnIYrRWIq   non-susceptible form
GEIYKRWIv   diminished response; susceptible form
GdIYKRWII   diminished response; susceptible form
GdIYKRWIv   diminished response; non-susceptible form; susceptible form
Epitope Name GEI
Species (MHC/HLA human(B*08:01)

Variant Details

Showing all: 7 variant(s).


Variant ID.  1805
Epitope Seq.  GEIYKRWII
Variant Seq.  GdIYrRWII
Mutations E/D K/R
Epitope Location E2D K5R
HXB2 Location E260D K263R
Mutation Type NSF: non-susceptible form
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note None of the patients tested responded to this variant.


Variant ID.  1806
Epitope Seq.  GEIYKRWII
Variant Seq.  rkIYKRWII
Mutations G/R E/K
Epitope Location G1R E2K
HXB2 Location G259R E260K
Mutation Type NSF: non-susceptible form
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note None of the patients tested responded to this variant.


Variant ID.  1807
Epitope Seq.  GEIYKRWII
Variant Seq.  GdIYrkWIv
Mutations E/D K/R R/K I/V
Epitope Location E2D K5R R6K I9V
HXB2 Location E260D K263R R264K I267V
Mutation Type NSF: non-susceptible form
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note None of the patients tested responded well to this variant.


Variant ID.  1808
Epitope Seq.  GEIYKRWII
Variant Seq.  GnIYrRWIq
Mutations E/N K/R I/Q
Epitope Location E2N K5R I9Q
HXB2 Location E260N K263R I267Q
Mutation Type NSF: non-susceptible form
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note None of the patients tested responded to this variant.


Variant ID.  1809
Epitope Seq.  GEIYKRWII
Variant Seq.  GEIYKRWIv
Mutations I/V
Epitope Location I9V
HXB2 Location I267V
Mutation Type DR: diminished response
SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note Some patients had response at the level of the response to the index peptide. 2 patients had about 50% of the original response.


Variant ID.  1810
Epitope Seq.  GEIYKRWII
Variant Seq.  GdIYKRWII
Mutations E/D
Epitope Location E2D
HXB2 Location E260D
Mutation Type DR: diminished response
SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note Some patients had response at the level of the response to the index peptide. 2 patients had about 50% of the original response.


Variant ID.  1811
Epitope Seq.  GEIYKRWII
Variant Seq.  GdIYKRWIv
Mutations E/D I/V
Epitope Location E2D I9V
HXB2 Location E260D I267V
Mutation Type DR: diminished response
NSF: non-susceptible form
SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note One patient responded at 80% of original response, 2 at 60%, 1 at 40% and 1 at 10%.

References

Turnbull2006 Emma L. Turnbull, A. Ross Lopes, Nicola A. Jones, David Cornforth, Phillipa Newton, Diana Aldam, Pierre Pellegrino, Jo Turner, Ian Williams, Craig M. Wilson, Paul A. Goepfert, Mala K. Maini, and Persephone Borrow. HIV-1 Epitope-Specific CD8+ T Cell Responses Strongly Associated with Delayed Disease Progression Cross-Recognize Epitope Variants Efficiently. J. Immunol., 176(10):6130-6146, 15 May 2006. PubMed ID: 16670322. Show all entries for this paper.


Displaying record number 55009

HXB2 Location  Nef(73-82)   Nef Epitope Map
View variants at this location
Epitope QVPLRPMTYK   Epitope Alignment
Variants
QVPLRPMTeK   diminished response
QVPvRPMTYK   diminished response
QVPiRPMTYK   diminished response
QVPLRPMTYq   diminished response
QVPLRPMTrr   non-susceptible form
QVPLRPMTYr   non-susceptible form; susceptible form
hVPLRPMTYK   diminished response; susceptible form
Epitope Name QVP
Species (MHC/HLA human(A*03:01)

Variant Details

Showing all: 7 variant(s).


Variant ID.  1812
Epitope Seq.  QVPLRPMTYK
Variant Seq.  QVPLRPMTeK
Mutations Y/E
Epitope Location Y9E
HXB2 Location Y81E
Mutation Type DR: diminished response
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note All patients tested had response <60% of the response to the index peptide.


Variant ID.  1813
Epitope Seq.  QVPLRPMTYK
Variant Seq.  QVPvRPMTYK
Mutations L/V
Epitope Location L4V
HXB2 Location L76V
Mutation Type DR: diminished response
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note All patients tested had response less or equal of 60% of the response to the index peptide.


Variant ID.  1814
Epitope Seq.  QVPLRPMTYK
Variant Seq.  QVPiRPMTYK
Mutations L/I
Epitope Location L4I
HXB2 Location L76I
Mutation Type DR: diminished response
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note All patients tested had response less or equal of 60% of the response to the index peptide.


Variant ID.  1815
Epitope Seq.  QVPLRPMTYK
Variant Seq.  QVPLRPMTYq
Mutations K/Q
Epitope Location K10Q
HXB2 Location K82Q
Mutation Type DR: diminished response
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note All patients tested had response less or equal of 60% of the response to the index peptide.


Variant ID.  1816
Epitope Seq.  QVPLRPMTYK
Variant Seq.  QVPLRPMTrr
Mutations K/R Y/R
Epitope Location K10R Y9R
HXB2 Location K82R Y81R
Mutation Type NSF: non-susceptible form
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note All patients tested had response less than 20% of the response to the index peptide.


Variant ID.  1817
Epitope Seq.  QVPLRPMTYK
Variant Seq.  QVPLRPMTYr
Mutations K/R
Epitope Location K10R
HXB2 Location K82R
Mutation Type NSF: non-susceptible form
SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note Some patients tested had response comparable to the response to the index peptide, one patient had reduced response and two patients did not have a response.


Variant ID.  1818
Epitope Seq.  QVPLRPMTYK
Variant Seq.  hVPLRPMTYK
Mutations Q/H
Epitope Location Q1H
HXB2 Location Q73H
Mutation Type DR: diminished response
SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note Some patients tested had response comparable to the response to the index peptide, one patient had reduced response (60%) and one patients had a response of 20% of the response to the index peptide.

References

Turnbull2006 Emma L. Turnbull, A. Ross Lopes, Nicola A. Jones, David Cornforth, Phillipa Newton, Diana Aldam, Pierre Pellegrino, Jo Turner, Ian Williams, Craig M. Wilson, Paul A. Goepfert, Mala K. Maini, and Persephone Borrow. HIV-1 Epitope-Specific CD8+ T Cell Responses Strongly Associated with Delayed Disease Progression Cross-Recognize Epitope Variants Efficiently. J. Immunol., 176(10):6130-6146, 15 May 2006. PubMed ID: 16670322. Show all entries for this paper.


Displaying record number 55006

HXB2 Location  Nef(90-97)   Nef Epitope Map
View variants at this location
Epitope FLKEKGGL   Epitope Alignment
Variants
FLKEqGGL   non-susceptible form; susceptible form
FLKEtGGL   non-susceptible form; susceptible form
FLKEnGGL   diminished response; non-susceptible form
FLKEmGGL   diminished response; non-susceptible form; susceptible form
FLKEeGGL   diminished response; non-susceptible form
FLrEKGGL   diminished response; non-susceptible form
FLKdKGGL   non-susceptible form; susceptible form
Epitope Name FLK
Species (MHC/HLA human(B*08:01)

Variant Details

Showing all: 7 variant(s).


Variant ID.  1819
Epitope Seq.  FLKEKGGL
Variant Seq.  FLKEqGGL
Mutations K/Q
Epitope Location K5Q
HXB2 Location K94Q
Mutation Type NSF: non-susceptible form
SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note One patient had response comparable to the response to the index peptide, other had reduced or no response.


Variant ID.  1820
Epitope Seq.  FLKEKGGL
Variant Seq.  FLKEtGGL
Mutations K/T
Epitope Location K5T
HXB2 Location K94T
Mutation Type NSF: non-susceptible form
SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note One patient had response comparable to the response to the index peptide, other had reduced or no response.


Variant ID.  1821
Epitope Seq.  FLKEKGGL
Variant Seq.  FLKEnGGL
Mutations K/N
Epitope Location K5N
HXB2 Location K94N
Mutation Type DR: diminished response
NSF: non-susceptible form
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note All patients tested had either no response or response < 40% of response to the index peptide.


Variant ID.  1822
Epitope Seq.  FLKEKGGL
Variant Seq.  FLKEmGGL
Mutations K/M
Epitope Location K5M
HXB2 Location K94M
Mutation Type DR: diminished response
NSF: non-susceptible form
SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note All patients tested had either no response or response < 70% of response to the index peptide.


Variant ID.  1823
Epitope Seq.  FLKEKGGL
Variant Seq.  FLKEeGGL
Mutations K/E
Epitope Location K5E
HXB2 Location K94E
Mutation Type DR: diminished response
NSF: non-susceptible form
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note All patients tested had either no response or response < 40% of response to the index peptide.


Variant ID.  1824
Epitope Seq.  FLKEKGGL
Variant Seq.  FLrEKGGL
Mutations K/R
Epitope Location K3R
HXB2 Location K92R
Mutation Type DR: diminished response
NSF: non-susceptible form
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note All patients tested had either no response or response < 60% of response to the index peptide.


Variant ID.  1825
Epitope Seq.  FLKEKGGL
Variant Seq.  FLKdKGGL
Mutations E/D
Epitope Location E4D
HXB2 Location E93D
Mutation Type NSF: non-susceptible form
SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Tetramer binding
Note One patient responded at the level of the response to the index peptide, Other patients had < 40% of original response.

References

Turnbull2006 Emma L. Turnbull, A. Ross Lopes, Nicola A. Jones, David Cornforth, Phillipa Newton, Diana Aldam, Pierre Pellegrino, Jo Turner, Ian Williams, Craig M. Wilson, Paul A. Goepfert, Mala K. Maini, and Persephone Borrow. HIV-1 Epitope-Specific CD8+ T Cell Responses Strongly Associated with Delayed Disease Progression Cross-Recognize Epitope Variants Efficiently. J. Immunol., 176(10):6130-6146, 15 May 2006. PubMed ID: 16670322. Show all entries for this paper.


Questions or comments? Contact us at immuno@lanl.gov
 
Managed by Triad National Security, LLC for the U.S. Department of Energy’s National Nuclear Security Administration
Copyright © 2022 Triad National Security, LLC | Disclaimer/Privacy

Dept of Health & Human Services Los Alamos National Institutes of Health